Snow Software Introduces New Global Partner Program to Drive Exponential Growth in Channel Ecosystem
1.2.2023 17:00:00 EET | Business Wire | Press release
Snow Software, the global leader in technology intelligence, today announced a new global partner program designed to enable partners to support customers as they face complex market challenges around managing cost and mitigating risk, while delivering value more efficiently and effectively with Snow. The new program aims to drive exponential growth in the Snow channel ecosystem, creating new opportunities for partners to tap into an estimated and growing $11.5 billion Technology Intelligence market.
Developed in collaboration with its current channel ecosystem, the new Snow partner program includes better support for multiple business models of partners, encouraging the creation of value-added services and driving tangible customer success by leveraging Snow technology. The program includes more partner incentives and rewards than the current program, while streamlining collaboration with Snow to better deliver value to shared customers.
“Today’s economic climate demands more from every organization’s IT technology environment, which means that our partners have a greater responsibility to provide visibility, governance and optimization services for their customers,” said Vinod Chumber, Vice President of Ecosystem Sales at Snow. “In order to ensure our partners can deliver excellent outcomes, it was essential to create a new program that better enabled them with the right resources, education and solutions to succeed. As a partner-centric organization, we believe that our new program combined with our Snow Atlas platform is a powerful combination to address the turbulent market customers and partners face today. The new program is just the beginning as we continue to invest in our partners and create a rich ecosystem enabled to take advantage of the vision for Technology Intelligence.”
Creating transparency with the market, the partner portal will feature real-time dashboards featuring each partner’s strong record of success and specializations to arm customers with insight on the best partners suited to their needs. The new framework will remove channel conflicts, empowering partners to build new, value-add services and work closely with the Snow wider teams to drive customer success. Additional new program benefits include:
- Sales rewards and points system to recognize the investment that individuals within the partner organization are making;
- Self-service capabilities to create new operational efficiencies within the partner portal;
- Business development funds to market and promote partner sales offerings built on top of Snow technology;
- Shadowing programs to drive customer success and adoption of Snow best practices and certification opportunities;
- Free access to Snow e-learning to empower partners with the latest knowledge on the Snow product and solution portfolio;
- Snow Champion Program to recognize and reward individuals for their contribution to the Snow community; and
- Ongoing recognition and rewards opportunities including annual partner awards to celebrate the success, rewards for joint customer success stories and more.
“Our clients need powerful solutions and tools to deliver tangible business value, reduce overall IT costs and mitigate risks,” said Shadi Khoshab, Global Director, ITAM & Software Sourcing Services at SoftwareOne. “By enhancing and innovating its partner program, Snow is demonstrating its commitment to our strategic relationship and helping to drive our joint business forward, empowering our clients with invaluable, actionable insights that underpins successful digital transformation.”
In addition to the overall program, Snow is committed to releasing ongoing product capabilities specifically aimed at enabling its partner community. Most recently, Snow introduced two new Snow Atlas capabilities for partners to better support their customers with improved collaboration features. Customers can now give partners direct access to their Snow Atlas platform, allowing partners to manage customer environments in the cloud. In addition, partners can now create agent packages with a self-service tool in Snow Atlas without engaging Snow Support, making the end-to-end delivery more efficient.
The new Snow partner program will be available for all partners later this year. For more information about the Snow partner ecosystem or to become a Snow partner, please visit: https://www.snowsoftware.com/global-partner-program/.
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005359/en/
Contact information
Rachel Austin
Snow Software
press@snowsoftware.com
Taylor Champlin
PAN Communications
snow@pancomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
